Tecvayli

Pharma

J&J bispecific combo delivers 89% PFS benefit in myeloma

An 89% progression-free survival improvement and a 62% overall survival benefit topline Tecvayli and Talvey’s MonumenTAL-6 readout in earlier myeloma.

Angus Liu Jul 23, 2026 8:30am

Why Legend Biotech stock fell 10% despite record Carvykti sales

Jul 20, 2026 11:11am

Legend sloughs off Carvykti threat from J&J's Tecvayli

Mar 12, 2026 2:00pm

Tecvayli-Darzalex combo earns national priority nod from FDA

Mar 6, 2026 8:00am

Johnson & Johnson's Tecvayli struts its stuff as a monotherapy

Jan 15, 2026 10:15am

FDA 'proactively' awards J&J a national priority review voucher

Dec 15, 2025 12:33pm